CLINICAL_TRIALS
trial_result
· 2025-12-18
Clinical Trial Update: Study of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff Tendinopathy [Phase 3]
Summary
Phase 3 trial evaluating Secukinumab for moderate-to-severe rotator cuff tendinopathy was terminated. Results from the study have been posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Novartis Pharmaceuticals | Conditions: Rotator Cuff Tendinopathy | Phase 3 | Status: TERMINATED | Results posted: 2025-12-18